T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
Essays in Biochemistry · 28.09.2023 · 67 (6) · 967-977
DOI: 10.1042/ebc20220247 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Essays in Biochemistry, online erschienen am 28.09.2023. Verfasst von Thomas A E Elliot und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, U.K. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust.
Abstract (Originalsprache)
Immune checkpoint immunotherapies act to block inhibitory receptors on the surface of T cells and other cells of the immune system. This can increase activation of immune cells and promote tumour clearance. Whilst this is very effective in some types of cancer, significant proportions of patients do not respond to single-agent immunotherapy. To improve patient outcomes, we must first mechanistically understand what drives therapy resistance. Many studies have utilised genetic, transcriptional, and histological signatures to find correlates of effective responses to treatment. It is key that we understand pretreatment predictors of response, but also to understand how the immune system becomes treatment resistant during therapy. Here, we review our understanding of the T-cell signatures that are critical for response, how these immune signatures change during treatment, and how this information can be used to rationally design therapeutic strategies. We highlight how chronic antigen recognition drives heterogeneous T-cell exhaustion and the role of T-cell receptor (TCR) signal strength in exhausted T-cell differentiation and molecular response to therapy. We explore how dynamic changes in negative feedback pathways can promote resistance to single-agent therapy. We speculate that this resistance may be circumvented in the future through identifying the most effective combinations of immunotherapies to promote sustained and durable antitumour responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, U.K.
ORCID-Profile: David Bending
Förderung
- Medical Research Council
- Wellcome Trust
Zitieren
APA
Elliot, T. A. E., Lecky, D. A. J., & Bending, D. (2023). T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures. Essays in Biochemistry, 67(6), 967-977. https://doi.org/10.1042/ebc20220247
Vancouver
Elliot TAE, Lecky DAJ, Bending D. T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures. Essays in Biochemistry. 2023;67(6):967-977. doi:10.1042/ebc20220247
BibTeX
@article{Elliot2023,
author = {Elliot, Thomas A E and Lecky, David A J and Bending, David},
title = {T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures},
journal = {Essays in Biochemistry},
year = {2023},
volume = {67},
number = {6},
pages = {967--977},
doi = {10.1042/ebc20220247}
}
EUVIMED